Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

Int Forum Allergy Rhinol. 2022 Mar;12(3):310-312. doi: 10.1002/alr.22904. Epub 2021 Oct 1.

Authors

Lauren T Roland¹, Sarah K Wise², Heqiong Wang³, Christina Mehta³, John M DelGaudio², Joshua M Levy²

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA.
² Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, GA.
³ Department of Biostatistics, Emory University, Atlanta, GA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Asthma* / drug therapy
Chronic Disease
Health Care Costs
Humans
Insurance Claim Review
Nasal Polyps* / drug therapy
Omalizumab / therapeutic use
Rhinitis* / drug therapy
Sinusitis* / drug therapy

Substances

Omalizumab

Grants and funding